newsfilter
← Latest News
GlobeNewswire·

Minerva Neurosciences Provides Third Quarter 2026 Financial Results and Business Updates

NERV
  • Minerva Neurosciences reported third-quarter 2026 financial results & business updates for the period ended September 30, 2026.
  • The confirmatory Phase 3 trial of roluperidone (MIN-101C19) for schizophrenia negative symptoms is ongoing with topline efficacy data expected in the second half of 2027.
  • Roluperidone remains the only late-stage drug candidate targeting negative symptoms directly in this high-need population.
  • The C19 Study will enroll 380 patients across approximately 40 global sites & includes Phase A (12-week placebo-controlled) & Phase B (52-week active-controlled relapse evaluation).
  • Phase A topline data is expected in 2H 2027, while Phase B topline data is expected in 2H 2028.
  • CEO Remy Luthringer & CMO Michael Davidson published an article in Schizophrenia Research advocating for non-dopaminergic mechanisms & improved trial methodology for negative symptoms.
  • Minerva will host an in-person & virtual Key Opinion Leader event on November 12, 2026, at 10:00 AM ET in New York.
  • R&D expense was $5.2 million for the three months ended September 30, 2026, compared to $0.9 million in the prior year period.
  • G&A expense was $4.3 million for the three months ended September 30, 2026, compared to $1.9 million in the prior year period.
  • GAAP net income for the three months ended September 30, 2026, was $100.7 million, driven by a $109.6 million non-cash gain on warrant liability changes.
  • Adjusted non-GAAP net loss for the three months ended September 30, 2026, was $5.6 million.
  • Cash, cash equivalents, marketable securities, & restricted cash totaled approximately $77.0 million as of September 30, 2026.
Company
Minerva Neurosciences, Inc
Keywords
Nasdaq:NERV, Minerva Neurosciences, Inc